The drug tegaserod maleate marketed as Zelnorm by Novartis and widely prescribed for irritable bowel syndrome was withdrawn from the US market in March this year by the US FDA (Food and Drug Administration). This was due to a link between Zelnorm and an increase in “ischemic cardiovascular events”, meaning reduced blood supply to some [...]